FierceBiotech ١٩ مارس ٢٠٢٦ Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals
FierceBiotech ١٩ مارس ٢٠٢٦ Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
Endpoints News ١٩ مارس ٢٠٢٦ Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
BioPharma Dive ١٢ مارس ٢٠٢٦ Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
Endpoints News ١٢ مارس ٢٠٢٦ Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News ١١ مارس ٢٠٢٦ Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Pharmaron ١١ مارس ٢٠٢٦ Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Endpoints News ٦ مارس ٢٠٢٦ Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News ٢٦ فبراير ٢٠٢٦ Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
Endpoints News ٢٤ فبراير ٢٠٢٦ Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
BioPharma Dive ٢٣ فبراير ٢٠٢٦ Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Endpoints News ٢٣ فبراير ٢٠٢٦ Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial